231 related articles for article (PubMed ID: 21334874)
1. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
Reuben JM; Lee BN; Gao H; Cohen EN; Mego M; Giordano A; Wang X; Lodhi A; Krishnamurthy S; Hortobagyi GN; Cristofanilli M; Lucci A; Woodward WA
Eur J Cancer; 2011 Jul; 47(10):1527-36. PubMed ID: 21334874
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients.
Giordano A; Gao H; Cohen EN; Anfossi S; Khoury J; Hess K; Krishnamurthy S; Tin S; Cristofanilli M; Hortobagyi GN; Woodward WA; Lucci A; Reuben JM
Ann Oncol; 2013 Oct; 24(10):2515-2521. PubMed ID: 23798614
[TBL] [Abstract][Full Text] [Related]
3. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
5. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
[TBL] [Abstract][Full Text] [Related]
8. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY
Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow.
De Giorgi U; Cohen EN; Gao H; Mego M; Lee BN; Lodhi A; Cristofanilli M; Lucci A; Reuben JM
Cancer Biol Ther; 2011 May; 11(9):812-5. PubMed ID: 21358274
[TBL] [Abstract][Full Text] [Related]
10. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
[TBL] [Abstract][Full Text] [Related]
11. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
Croker AK; Goodale D; Chu J; Postenka C; Hedley BD; Hess DA; Allan AL
J Cell Mol Med; 2009 Aug; 13(8B):2236-2252. PubMed ID: 18681906
[TBL] [Abstract][Full Text] [Related]
12. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
13. High GD2 expression defines breast cancer cells with enhanced invasiveness.
Mansoori M; Roudi R; Abbasi A; Abolhasani M; Abdi Rad I; Shariftabrizi A; Madjd Z
Exp Mol Pathol; 2019 Aug; 109():25-35. PubMed ID: 31075227
[TBL] [Abstract][Full Text] [Related]
14. [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer].
Gong JF; Yuan YH; Song GH; Yu J; Han Y; Jia J; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):465-70. PubMed ID: 18931706
[TBL] [Abstract][Full Text] [Related]
15. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
16. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
17. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
18. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer stem cell population in different molecular subtypes of breast cancer.
Gupta P; Singh V; Kumar S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):199-203. PubMed ID: 35068436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
